Oncology · Phase 2-3 · pulled 2026-11-06

Ovarian cancer: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of ovarian cancer (last 12 years), plus 300 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Ovarian cancer: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	MD Anderson Cancer Center Houston, United States · 16 spellings merged	41 16 completed, 25 terminated	NCT05325866 NCT06171789 NCT02611024 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT06171789 PRO1107 in Patients With Advanced Solid Tumors terminated 2025-08-18 Stop reason on the record: “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation” NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors completed 2025-07-01 NCT04902872 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors completed 2025-06-24 NCT02520154 Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer completed 2025-05-22 NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors terminated 2025-04-30 Stop reason on the record: “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”	2026-01-28	46 NCT06760819 NCT06695845 NCT06072781 NCT05564377	83
2	Massachusetts General Hospital Boston, United States · 9 spellings merged	32 17 completed, 15 terminated	NCT04729387 NCT03834272 NCT06171789 6 trials with titles NCT04729387 Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected terminated 2026-01-19 Stop reason on the record: “Sponsor Decision” NCT03834272 Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies completed 2025-08-19 NCT06171789 PRO1107 in Patients With Advanced Solid Tumors terminated 2025-08-18 Stop reason on the record: “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation” NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors completed 2025-07-01 NCT05563272 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors terminated 2025-05-09 Stop reason on the record: “Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic component in the study design.” NCT04718675 A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) terminated 2025-02-07 Stop reason on the record: “Due to lack of safety and futility”	2026-01-19	27 NCT06787612 NCT05579366 NCT06819007 NCT07109726	88
3	University of Oklahoma Health Sciences Center Oklahoma City, United States · 27 spellings merged	30 16 completed, 14 terminated	NCT06169124 NCT05601752 NCT05451849 6 trials with titles NCT06169124 Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors completed 2026-09-28 NCT05601752 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) terminated 2026-09-24 Stop reason on the record: “Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.” NCT05451849 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer terminated 2025-08-30 Stop reason on the record: “No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear signal of robust clinical activity.” NCT02498600 Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer completed 2025-07-26 NCT05348356 Nirogacestat in Ovarian Granulosa Cell Tumors completed 2025-07-14 NCT05523440 Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation terminated 2025-01-08 Stop reason on the record: “Funding issue”	2026-09-28	42 NCT07504588 NCT04550494 NCT05579366 NCT05112601	74
4	Memorial Sloan Kettering Cancer Center New York, United States · 21 spellings merged	30 15 completed, 15 terminated	NCT06433219 NCT04729387 NCT05007106 6 trials with titles NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) completed 2026-08-11 NCT04729387 Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected terminated 2026-01-19 Stop reason on the record: “Sponsor Decision” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT02498600 Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer completed 2025-07-26 NCT05348356 Nirogacestat in Ovarian Granulosa Cell Tumors completed 2025-07-14 NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) terminated 2025-05-08 Stop reason on the record: “Study terminated due to business and strategic decision.”	2026-08-11	44 NCT01223248 NCT07213804 NCT06695845 NCT06072781	80
5	Tennessee Oncology, PLLC Nashville, United States · 20 spellings merged	30 11 completed, 19 terminated	NCT05180474 NCT04729387 NCT05708950 6 trials with titles NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT04729387 Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected terminated 2026-01-19 Stop reason on the record: “Sponsor Decision” NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) completed 2025-12-18 NCT04718675 A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) terminated 2025-02-07 Stop reason on the record: “Due to lack of safety and futility” NCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors completed 2025-01-13 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20	2026-03-25	14 NCT05579366 NCT06819007 NCT07109726 NCT04561362	80
6	Dana-Farber Cancer Institute Boston, United States · 11 spellings merged	29 15 completed, 14 terminated	NCT04729387 NCT03462342 NCT05348356 6 trials with titles NCT04729387 Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected terminated 2026-01-19 Stop reason on the record: “Sponsor Decision” NCT03462342 Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer completed 2025-07-21 NCT05348356 Nirogacestat in Ovarian Granulosa Cell Tumors completed 2025-07-14 NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer completed 2025-04-14 NCT04718675 A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) terminated 2025-02-07 Stop reason on the record: “Due to lack of safety and futility” NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20	2026-01-19	34 NCT05579366 NCT05296512 NCT06760819 NCT06619236	88
7	Princess Margaret Cancer Centre Toronto, Canada · 21 spellings merged	25 12 completed, 13 terminated	NCT05601752 NCT03740165 NCT05325866 6 trials with titles NCT05601752 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) terminated 2026-09-24 Stop reason on the record: “Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.” NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) completed 2026-04-14 NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04260802 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers terminated 2025-11-07 Stop reason on the record: “Business Decision” NCT05870748 REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 terminated 2025-08-26 Stop reason on the record: “Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety o” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05	2026-09-24	26 NCT06787612 NCT04918186 NCT07213804 NCT06760819	81
8	Gustave Roussy Villejuif, France · 11 spellings merged	24 17 completed, 7 terminated	NCT05601752 NCT06433219 NCT03740165 6 trials with titles NCT05601752 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) terminated 2026-09-24 Stop reason on the record: “Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.” NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) completed 2026-08-11 NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) completed 2026-04-14 NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT05198804 A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer completed 2026-01-19	2026-09-24	24 NCT06760819 NCT06619236 NCT04713514 NCT05128825	91
9	Hospital Universitari Vall d'Hebron Barcelona, Spain · 25 spellings merged	23 18 completed, 5 terminated	NCT05601752 NCT06433219 NCT05180474 6 trials with titles NCT05601752 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) terminated 2026-09-24 Stop reason on the record: “Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.” NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) completed 2026-08-11 NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors completed 2025-07-01 NCT03353831 Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer completed 2025-03-11 NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors terminated 2024-11-29 Stop reason on the record: “Due to lack of expected efficacy shown at the time of the interim analysis”	2026-09-24	23 NCT06695845 NCT06843447 NCT06819007 NCT06172478	90
10	University of Chicago Comprehensive Cancer Center Chicago, United States · 15 spellings merged	22 12 completed, 10 terminated	NCT06433219 NCT03740165 NCT02498600 6 trials with titles NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) completed 2026-08-11 NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) completed 2026-04-14 NCT02498600 Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer completed 2025-07-26 NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression completed 2024-10-29 NCT04374630 Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian completed 2024-06-28 NCT02713386 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer completed 2024-05-22	2026-08-11	30 NCT06787612 NCT04918186 NCT05296512 NCT05112601	81
11	Karmanos Cancer Institute Detroit, United States · 5 spellings merged	21 13 completed, 8 terminated	NCT05601752 NCT05180474 NCT05198804 6 trials with titles NCT05601752 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) terminated 2026-09-24 Stop reason on the record: “Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.” NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05198804 A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer completed 2026-01-19 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) terminated 2025-05-08 Stop reason on the record: “Study terminated due to business and strategic decision.” NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer completed 2025-04-14	2026-09-24	18 NCT06787612 NCT05579366 NCT07213804 NCT06695845	87
12	Istituto Europeo di Oncologia Milan, Italy · 19 spellings merged	21 15 completed, 6 terminated	NCT06433219 NCT03740165 NCT05180474 6 trials with titles NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) completed 2026-08-11 NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) completed 2026-04-14 NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression completed 2024-10-29 NCT05446870 Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) completed 2024-10-16	2026-08-11	15 NCT07213804 NCT06760819 NCT06072781 NCT05128825	82
13	UZ Leuven Leuven, Belgium · 16 spellings merged	21 15 completed, 6 terminated	NCT06433219 NCT03740165 NCT05180474 6 trials with titles NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) completed 2026-08-11 NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) completed 2026-04-14 NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT03353831 Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer completed 2025-03-11 NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors terminated 2024-11-29 Stop reason on the record: “Due to lack of expected efficacy shown at the time of the interim analysis”	2026-08-11	20 NCT07213804 NCT06619236 NCT06303505 NCT04713514	83
14	The Christie NHS Foundation Trust Manchester, United Kingdom · 13 spellings merged	20 15 completed, 5 terminated	NCT05601752 NCT06433219 NCT05180474 6 trials with titles NCT05601752 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) terminated 2026-09-24 Stop reason on the record: “Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.” NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) completed 2026-08-11 NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) terminated 2025-05-08 Stop reason on the record: “Study terminated due to business and strategic decision.” NCT07648745 Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer completed 2025-01-14	2026-09-24	18 NCT07213804 NCT06072781 NCT06843447 NCT06819007	89
15	Women and Infants Hospital Providence, United States · 10 spellings merged	20 12 completed, 8 terminated	NCT03740165 NCT05198804 NCT02498600 6 trials with titles NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) completed 2026-04-14 NCT05198804 A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer completed 2026-01-19 NCT02498600 Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer completed 2025-07-26 NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression completed 2024-10-29 NCT04374630 Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian completed 2024-06-28 NCT05001282 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) terminated 2024-06-07 Stop reason on the record: “Lack of Funding - no safety issue with Drug; Company Permanently Closed”	2026-04-14	24 NCT05579366 NCT05112601 NCT07213804 NCT05564377	82
16	Washington University School of Medicine St Louis, United States · 12 spellings merged	19 10 completed, 9 terminated	NCT03740165 NCT02498600 NCT04718675 6 trials with titles NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) completed 2026-04-14 NCT02498600 Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer completed 2025-07-26 NCT04718675 A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) terminated 2025-02-07 Stop reason on the record: “Due to lack of safety and futility” NCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors completed 2025-01-13 NCT05446870 Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) completed 2024-10-16 NCT02713386 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer completed 2024-05-22	2026-04-14	34 NCT05112601 NCT06072781 NCT05564377 NCT06915025	85
17	Centre Leon Berard Lyon, France · 13 spellings merged	18 15 completed, 3 terminated	NCT05601752 NCT02598219 NCT06433219 6 trials with titles NCT05601752 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) terminated 2026-09-24 Stop reason on the record: “Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.” NCT02598219 Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. completed 2026-08-26 NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) completed 2026-08-11 NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors completed 2025-07-01	2026-09-24	25 NCT06072781 NCT04713514 NCT05128825 NCT06819007	95
18	Hospital Universitario HM Sanchinarro Madrid, Spain · 28 spellings merged	18 12 completed, 6 terminated	NCT05601752 NCT05180474 NCT02611024 6 trials with titles NCT05601752 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) terminated 2026-09-24 Stop reason on the record: “Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.” NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors completed 2025-07-01 NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) terminated 2025-05-08 Stop reason on the record: “Study terminated due to business and strategic decision.” NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors terminated 2024-11-29 Stop reason on the record: “Due to lack of expected efficacy shown at the time of the interim analysis” NCT04731467 A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors completed 2024-09-30	2026-09-24	19 NCT07213804 NCT06760819 NCT05086692 NCT06843447	83
19	Yale University New Haven, United States · 20 spellings merged	18 10 completed, 8 terminated	NCT03740165 NCT05180474 NCT02498600 6 trials with titles NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) completed 2026-04-14 NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT02498600 Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer completed 2025-07-26 NCT04902872 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors completed 2025-06-24 NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression completed 2024-10-29 NCT05259696 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) completed 2024-10-24	2026-04-14	24 NCT06619236 NCT06072781 NCT06843447 NCT03348631	87
20	Arizona Oncology Associates, PC - HOPE Tucson, United States · 13 spellings merged	18 10 completed, 8 terminated	NCT05198804 NCT05870748 NCT05092360 6 trials with titles NCT05198804 A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer completed 2026-01-19 NCT05870748 REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 terminated 2025-08-26 Stop reason on the record: “Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety o” NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) terminated 2025-05-08 Stop reason on the record: “Study terminated due to business and strategic decision.” NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors terminated 2025-04-30 Stop reason on the record: “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.” NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression completed 2024-10-29 NCT04374630 Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian completed 2024-06-28	2026-01-19	2 NCT05579366 NCT02446600	79
21	University College London Hospital London, United Kingdom · 10 spellings merged	17 11 completed, 6 terminated	NCT05601752 NCT05180474 NCT05092360 6 trials with titles NCT05601752 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) terminated 2026-09-24 Stop reason on the record: “Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.” NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) terminated 2025-05-08 Stop reason on the record: “Study terminated due to business and strategic decision.” NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression completed 2024-10-29 NCT02601950 A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma completed 2024-02-26 NCT03117933 Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer completed 2023-12-31	2026-09-24	8 NCT06072781 NCT06161025 NCT07214779 NCT07318558	84
22	University of Virginia Cancer Center Charlottesville, United States · 9 spellings merged	17 11 completed, 6 terminated	NCT05198804 NCT05092360 NCT05523440 6 trials with titles NCT05198804 A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer completed 2026-01-19 NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) terminated 2025-05-08 Stop reason on the record: “Study terminated due to business and strategic decision.” NCT05523440 Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation terminated 2025-01-08 Stop reason on the record: “Funding issue” NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression completed 2024-10-29 NCT02713386 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer completed 2024-05-22 NCT03602586 Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer completed 2024-03-27	2026-01-19	21 NCT05112601 NCT06072781 NCT05564377 NCT06843447	84
23	Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, United States · 22 spellings merged	17 7 completed, 10 terminated	NCT05870748 NCT05092360 NCT05572684 6 trials with titles NCT05870748 REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 terminated 2025-08-26 Stop reason on the record: “Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety o” NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) terminated 2025-05-08 Stop reason on the record: “Study terminated due to business and strategic decision.” NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors terminated 2025-04-30 Stop reason on the record: “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.” NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20 NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) completed 2024-10-28 NCT05446870 Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) completed 2024-10-16	2025-08-26	23 NCT07213804 NCT06619236 NCT05564377 NCT06819007	79
24	Ohio State University Comprehensive Cancer Center Columbus, United States · 24 spellings merged	17 6 completed, 11 terminated	NCT05870748 NCT05092360 NCT03602586 6 trials with titles NCT05870748 REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 terminated 2025-08-26 Stop reason on the record: “Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety o” NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) terminated 2025-05-08 Stop reason on the record: “Study terminated due to business and strategic decision.” NCT03602586 Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer completed 2024-03-27 NCT04383210 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors terminated 2024-02-28 Stop reason on the record: “Business decision” NCT04729608 Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer terminated 2023-08-04 Stop reason on the record: “There were no significant differences in median PFS between batiraxcept + paclitaxel or paclitaxel alone arms. There was no detriment to overall survival. No new safety signals were identified.” NCT03940196 Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) completed 2023-05-18	2025-08-26	38 NCT05579366 NCT05112601 NCT06303505 NCT05564377	78
25	Cleveland Clinic Foundation Cleveland, United States · 17 spellings merged	16 11 completed, 5 terminated	NCT06169124 NCT05601752 NCT02498600 6 trials with titles NCT06169124 Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors completed 2026-09-28 NCT05601752 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) terminated 2026-09-24 Stop reason on the record: “Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.” NCT02498600 Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer completed 2025-07-26 NCT04718675 A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) terminated 2025-02-07 Stop reason on the record: “Due to lack of safety and futility” NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression completed 2024-10-29 NCT05001282 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) terminated 2024-06-07 Stop reason on the record: “Lack of Funding - no safety issue with Drug; Company Permanently Closed”	2026-09-28	28 NCT05112601 NCT07213804 NCT06760819 NCT06619236	78

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Ovarian cancer: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Amir A Jazaeri M.D. Anderson Cancer Center	5	NCT04019288 NCT03610490 NCT03318900 NCT03026062 NCT02520154	PMID 42259216 International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2026 · High match PMID 41528970 Clinical cancer research : an official journal of the American Association for Cancer Research, 2026 · High match PMID 41042068 Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025 · High match
2	Alexander Philipovskiy Florida Cancer Specialists & Research Institute	4	NCT06257758 NCT05185947 NCT03456700 NCT02487095	No paper matched at High or Medium confidence
3	John B. Liao Fred Hutch/University of Washington Cancer Consortium	3	NCT04387227 NCT03029611 NCT03029598	PMID 42135959 Journal of gynecologic oncology, 2026 · High match PMID 40221173 Gynecologic oncology, 2025 · High match PMID 39362046 Gynecologic oncology, 2024 · High match
4	Jie Jiang Qilu Hospital of Shandong University	3	NCT06173037 NCT02889900 NCT02312245	PMID 42736545 BMC cancer, 2026 · High match PMID 42721822 Phytomedicine : international journal of phytotherapy and phytopharmacology, 2026 · Medium match PMID 42362198 IET systems biology, 2026 · High match
5	Emese Zsiros Roswell Park Cancer Institute	3	NCT02953457 NCT03685695 NCT02853318	PMID 42512432 Cancers, 2026 · High match PMID 41974150 Lancet (London, England), 2026 · High match PMID 41513408 Journal for immunotherapy of cancer, 2026 · High match
6	Ursula Matulonis Dana-Farber Cancer Institute	3	NCT04296890 NCT02915523 NCT02865811	PMID 42875558 Nature medicine, 2026 · High match PMID 40666988 bioRxiv : the preprint server for biology, 2025 · High match PMID 40273550 Gynecologic oncology, 2025 · High match
7	Lingying Wu Chinese Academy of Medical Sciences and Peking Union Medical College	3	NCT04999605 NCT04392102 NCT03863860	PMID 42707988 Theranostics, 2026 · High match PMID 42570087 Abdominal radiology (New York), 2026 · Medium match PMID 42566833 Biomaterials advances, 2026 · Medium match
8	Lung-Ji Chang Shenzhen Geno-Immune Medical Institute	2	NCT03362606 NCT03184753	No paper matched at High or Medium confidence
9	Rushad Patell Beth Israel Deaconess Medical Center	2	NCT04339140 NCT03532139	PMID 40845270 Blood advances, 2025 · High match PMID 40472284 Blood advances, 2026 · High match
10	Nicoletta Colombo Istituto Europeo di Oncologia (IEO) - Milan	2	NCT03891576 NCT03314740	PMID 42705254 The Lancet. Oncology, 2026 · High match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.